- Home
- STOK vs AMSF Comparison
STOK vs AMSF Comparison
Compare STOK & AMSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- AMSF
- Stock Information
- Founded
- STOK 2014
- AMSF 1985
- Country
- STOK United States
- AMSF United States
- Employees
- STOK N/A
- AMSF N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- AMSF Accident &Health Insurance
- Sector
- STOK Health Care
- AMSF Finance
- Exchange
- STOK Nasdaq
- AMSF Nasdaq
- Market Cap
- STOK 997.9M
- AMSF 857.2M
- IPO Year
- STOK 2019
- AMSF 2005
- Fundamental
- Price
- STOK $19.76
- AMSF $46.18
- Analyst Decision
- STOK Strong Buy
- AMSF Buy
- Analyst Count
- STOK 6
- AMSF 2
- Target Price
- STOK $26.60
- AMSF $57.50
- AVG Volume (30 Days)
- STOK 920.7K
- AMSF 78.4K
- Earning Date
- STOK 08-12-2025
- AMSF 10-22-2025
- Dividend Yield
- STOK N/A
- AMSF 9.89%
- EPS Growth
- STOK N/A
- AMSF N/A
- EPS
- STOK 0.91
- AMSF 2.63
- Revenue
- STOK $199,893,000.00
- AMSF $306,470,000.00
- Revenue This Year
- STOK $415.58
- AMSF $2.98
- Revenue Next Year
- STOK N/A
- AMSF $5.32
- P/E Ratio
- STOK $21.55
- AMSF $17.52
- Revenue Growth
- STOK 1218.82
- AMSF N/A
- 52 Week Low
- STOK $5.35
- AMSF $42.48
- 52 Week High
- STOK $20.00
- AMSF $60.24
- Technical
- Relative Strength Index (RSI)
- STOK 78.62
- AMSF 55.31
- Support Level
- STOK $19.07
- AMSF $45.59
- Resistance Level
- STOK $19.91
- AMSF $46.64
- Average True Range (ATR)
- STOK 1.26
- AMSF 0.78
- MACD
- STOK 0.14
- AMSF 0.03
- Stochastic Oscillator
- STOK 96.55
- AMSF 66.18
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
About AMSF AMERISAFE Inc.
AMERISAFE Inc is a specialty provider of workers' compensation insurance focused on small to mid-sized employers engaged in hazardous industries, principally construction, trucking, logging and lumber, agriculture, manufacturing, maritime, and telecommunications. The company generates a majority of its revenue in the form of premiums.